PDACatch®
Discover PDACatch®, a groundbreaking liquid biopsy assay granted FDA Breakthrough Device Designation for the early detection of pancreatic adenocarcinoma (PDAC) in high-risk individuals. PDACatch® utilizes proprietary DNA methylation technology to identify circulating tumor DNA, allowing for the early detection of PDAC and precancerous lesions. With a focus on transforming late-stage diagnoses, PDACatch® has demonstrated the potential to detect cancer four years before conventional methods. The FDA's Breakthrough Device Designation expedites its development, offering hope for timely screening.
BT-Reveal Early Pancreatic Cancer Test
The BT-Reveal Early Pancreatic Cancer Test, offered by BREAKTHROUGH GENOMICS in partnership with Singlera Genomics as the technology partner, utilizes PDACatch® to detect early stages of pancreatic cancer from a simple blood draw. This non-invasive test can identify extremely low concentrations of cancer signals, allowing for the diagnosis of the disease before symptoms appear and while it is still treatable through surgery and other methods. In April 2023, it was designated as a Breakthrough Device by the FDA. The test is available as a Laboratory Developed Test (LDT) from BREAKTHROUGH GENOMICS' CAP and CLIA-certified lab in Southern California, requiring just a 10ml blood sample that can be easily stored and transported at room temperature. For more information, please visit https://earlypancreaticcancertest.com.